Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07553663 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Pharmacokinetics and Safety of Miricorilant
A Phase 1 study, sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT07553663 is a Phase 1 study that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT07553663, a Phase 1 study, is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
- DRUG Miricorilant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07553663
The ClinicalTrials.gov registry entry for NCT07553663 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Miricorilant is the first listed.
NCT07553663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07553663 about?
NCT07553663 is a clinical study titled "Evaluating the Pharmacokinetics and Safety of Miricorilant". A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
What is the current status of trial NCT07553663?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-04-30. Estimated completion is 2026-10-30.
What interventions are being tested in trial NCT07553663?
The interventions under investigation include: Miricorilant (DRUG).
Who is sponsoring clinical trial NCT07553663?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.